These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38106909)

  • 41. Antibiotics associated with acquisition of carbapenem-resistant Pseudomonas aeruginosa in ICUs: a multicentre nested case-case-control study.
    Coppry M; Jeanne-Leroyer C; Noize P; Dumartin C; Boyer A; Bertrand X; Dubois V; Rogues AM
    J Antimicrob Chemother; 2019 Feb; 74(2):503-510. PubMed ID: 30376042
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carbapenem-Nonsusceptible
    Asempa TE; Nicolau DP; Kuti JL
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31118271
    [No Abstract]   [Full Text] [Related]  

  • 43. Influence of regular reporting on local Pseudomonas aeruginosa and Acinetobacter spp. sensitivity to antibiotics on consumption of antibiotics and resistance patterns.
    Djordjevic ZM; Folic MM; Jankovic SM
    J Clin Pharm Ther; 2017 Oct; 42(5):585-590. PubMed ID: 28556289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence, antimicrobial resistance and mortality of
    Xiao S; Liang X; Han L; Zhao S
    Front Public Health; 2023; 11():1294141. PubMed ID: 38249405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation between cefepime utilisation and Pseudomonas aeruginosa resistance rates to β-lactams and carbapenems in patients with healthcare-associated infections.
    Djordjevic ZM; Folic MM; Jankovic SM
    J Glob Antimicrob Resist; 2018 Jun; 13():60-64. PubMed ID: 29154953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of Carbapenemase Encoding Gene and Resistance to Cefiderocol in Hospital and Community eXtensive Drug Resistance and Carbapenem-Resistant
    Benzaarate I; El Otmani F; Khazaz A; Timinouni M; Bourjilat F; Bogaerts P; Huang TD; Nayme K
    Foodborne Pathog Dis; 2023 Oct; 20(10):460-466. PubMed ID: 37616567
    [No Abstract]   [Full Text] [Related]  

  • 47. Antibiotic resistance rates for Pseudomonas aeruginosa clinical respiratory and bloodstream isolates among the Veterans Affairs Healthcare System from 2009 to 2013.
    Appaneal HJ; Caffrey AR; Jiang L; Dosa D; Mermel LA; LaPlante KL
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):311-315. PubMed ID: 29310949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diverse Genetic Background of Multidrug-Resistant Pseudomonas aeruginosa from Mainland China, and Emergence of an Extensively Drug-Resistant ST292 Clone in Kunming.
    Fan X; Wu Y; Xiao M; Xu ZP; Kudinha T; Bazaj A; Kong F; Xu YC
    Sci Rep; 2016 May; 6():26522. PubMed ID: 27198004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Nosocomial infections caused by multiresistant Pseudomonas aeruginosa (carbapenems included): predictive and prognostic factors. A prospective study (2016-2017))].
    Hernández A; Yagüe G; García Vázquez E; Simón M; Moreno Parrado L; Canteras M; Gómez J
    Rev Esp Quimioter; 2018 Apr; 31(2):123-130. PubMed ID: 29564870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy.
    Ciofi Degli Atti M; Bernaschi P; Carletti M; Luzzi I; García-Fernández A; Bertaina A; Sisto A; Locatelli F; Raponi M
    BMC Infect Dis; 2014 Sep; 14():494. PubMed ID: 25209325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of blaGES-5 and bla veb-1 genes with multidrug-resistant extend, pandrug resistance patterns (MDR, XDR, PDR), and biofilm formation in Pseudomonas aeruginosa isolates.
    Ali FA; Bakir SH; Haji SH; Hussen BM
    Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):52-60. PubMed ID: 34933733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019.
    Lee YL; Ko WC; Hsueh PR
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0200021. PubMed ID: 34807753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    Int J Antimicrob Agents; 2023 May; 61(5):106772. PubMed ID: 36878411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.
    Kohlenberg A; Weitzel-Kage D; van der Linden P; Sohr D; Vögeler S; Kola A; Halle E; Rüden H; Weist K
    J Hosp Infect; 2010 Apr; 74(4):350-7. PubMed ID: 20170982
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL
    Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nosocomial spread of class 1 integron-carrying extensively drug-resistant Pseudomonas aeruginosa isolates in a Thai hospital.
    Kiddee A; Henghiranyawong K; Yimsabai J; Tiloklurs M; Niumsup PR
    Int J Antimicrob Agents; 2013 Oct; 42(4):301-6. PubMed ID: 23845503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States.
    Puzniak L; DePestel DD; Yu K; Ye G; Gupta V
    Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115172. PubMed ID: 33130502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.